LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.12 -2.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.09

Max

1.15

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+334.78% upside

Turustatistika
By TradingEconomics
Turukapital	-2.3M 123M
Eelmine avamishind	3.73
Eelmine sulgemishind	1.12

Uudiste sentiment

By Acuity

100%

354 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. dets 2025, 17:39 UTC

Suurimad hinnamuutused turgudel

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15. dets 2025, 23:44 UTC

Market Talk

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15. dets 2025, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

15. dets 2025, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15. dets 2025, 22:19 UTC

Market Talk

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15. dets 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

15. dets 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15. dets 2025, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15. dets 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Completes Acquisition Of Moveworks >NOW

15. dets 2025, 21:00 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15. dets 2025, 20:57 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15. dets 2025, 20:36 UTC

Market Talk

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15. dets 2025, 20:31 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15. dets 2025, 20:27 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15. dets 2025, 20:15 UTC

Market Talk

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15. dets 2025, 19:22 UTC

Market Talk

Gold and Silver Gain to Start Week -- Market Talk

15. dets 2025, 18:37 UTC

Market Talk

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15. dets 2025, 18:29 UTC

Market Talk

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15. dets 2025, 17:58 UTC

Market Talk

Canada Housing Market In Search Of a Bottom -- Market Talk

15. dets 2025, 17:36 UTC

Market Talk

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15. dets 2025, 17:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. dets 2025, 17:36 UTC

Tulu

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15. dets 2025, 17:30 UTC

Omandamised, ülevõtmised, äriostud

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

334.78% tõus

12 kuu keskmine prognoos

Keskmine 5 USD 334.78%

Kõrge 8 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

354 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.